Organon & Co. Stock-Based Compensation
Organon & Co. (OGN) reported Stock-Based Compensation of $44.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-31
- Organon & Co. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $25.00M, a 13.64% increase year-over-year.
- Organon & Co. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $19.00M, a 20.83% decline year-over-year.
- Organon & Co. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.00M, a 73.08% decline year-over-year.
- Organon & Co. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $24.00M, a 4.00% decline year-over-year.
- Organon & Co. share-based payment arrangement, noncash expense for fiscal 2025 was $77.00M, a 26.67% decline from fiscal 2024.
- Organon & Co. share-based payment arrangement, noncash expense for fiscal 2024 was $105.00M, a 3.96% increase from fiscal 2023.
- Organon & Co. share-based payment arrangement, noncash expense for fiscal 2023 was $101.00M, a 34.67% increase from fiscal 2022.
- Organon & Co. share-based payment arrangement, noncash expense for fiscal 2022 was $75.00M, a 27.12% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $44.00M 10-Q · filed 2026-07-31 | $51.00M derived: sum of 3 quarters · filed 2026-07-31 | $75.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $19.00M 10-Q · filed 2026-05-04 | $26.00M derived: sum of 2 quarters · filed 2026-05-04 | $50.00M derived: sum of 3 quarters · filed 2026-05-04 | $72.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $31.00M derived: sum of 2 quarters · filed 2026-02-24 | $53.00M derived: sum of 3 quarters · filed 2026-07-31 | $77.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $24.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $46.00M derived: sum of 2 quarters · filed 2026-07-31 | $70.00M 10-Q · filed 2025-11-10 | $96.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $22.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $46.00M 10-Q · filed 2026-07-31 | $72.00M derived: sum of 3 quarters · filed 2026-07-31 | $97.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $24.00M 10-Q · filed 2026-05-04 | $50.00M derived: sum of 2 quarters · filed 2026-05-04 | $75.00M derived: sum of 3 quarters · filed 2026-05-04 | $103.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $51.00M derived: sum of 2 quarters · filed 2026-02-24 | $79.00M derived: sum of 3 quarters · filed 2026-02-24 | $105.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $53.00M derived: sum of 2 quarters · filed 2025-11-10 | $79.00M 10-Q · filed 2025-11-10 | $106.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $28.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $54.00M 10-Q · filed 2025-08-06 | $81.00M derived: sum of 3 quarters · filed 2026-02-24 | $108.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $26.00M 10-Q · filed 2025-05-02 | $53.00M derived: sum of 2 quarters · filed 2026-02-24 | $80.00M derived: sum of 3 quarters · filed 2026-02-24 | $105.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $54.00M derived: sum of 2 quarters · filed 2026-02-24 | $79.00M derived: sum of 3 quarters · filed 2026-02-24 | $101.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $27.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $52.00M derived: sum of 2 quarters · filed 2024-11-01 | $74.00M 10-Q · filed 2024-11-01 | $97.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $47.00M 10-Q · filed 2024-08-07 | $70.00M derived: sum of 3 quarters · filed 2025-11-10 | $88.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $22.00M 10-Q · filed 2024-05-03 | $45.00M derived: sum of 2 quarters · filed 2025-11-10 | $63.00M derived: sum of 3 quarters · filed 2025-11-10 | $82.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $23.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $41.00M derived: sum of 2 quarters · filed 2025-11-10 | $60.00M derived: sum of 3 quarters · filed 2025-11-10 | $75.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $37.00M derived: sum of 2 quarters · filed 2023-11-03 | $52.00M 10-Q · filed 2023-11-03 | $67.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $34.00M 10-Q · filed 2023-08-09 | $49.00M derived: sum of 3 quarters · filed 2024-02-26 | $64.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $15.00M 10-Q · filed 2023-05-05 | $30.00M derived: sum of 2 quarters · filed 2024-02-26 | $45.00M derived: sum of 3 quarters · filed 2024-02-26 | $63.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $30.00M derived: sum of 2 quarters · filed 2024-02-26 | $48.00M derived: sum of 3 quarters · filed 2024-02-26 | $59.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $33.00M derived: sum of 2 quarters · filed 2022-11-04 | $44.00M 10-Q · filed 2022-11-04 | $52.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $29.00M 10-Q · filed 2022-08-05 | $37.00M derived: sum of 3 quarters · filed 2023-02-27 | $48.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $11.00M 10-Q · filed 2022-05-06 | $19.00M derived: sum of 2 quarters · filed 2023-02-27 | $30.00M derived: sum of 3 quarters · filed 2023-02-27 | $41.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $19.00M derived: sum of 2 quarters · filed 2023-02-27 | $30.00M derived: sum of 3 quarters · filed 2023-02-27 | $40.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $22.00M derived: sum of 2 quarters · filed 2021-11-12 | $32.00M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $21.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $10.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $41.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |